EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Endothelium as a Source of Cardiovascular Toxicity From Antitumor Kinase Inhibitors

Richard J Travers iD, Alec Stepanian iD, Iris Z Jaffe iD

Arteriosclerosis, Thrombosis, and Vascular Biology · 2024-10 · 44 (10) · 2143-2153

DOI: 10.1161/atvbaha.124.319864 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2024-10. Verfasst von Richard J Travers und 2 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Cardiology Research Institute (R.J.T., A.S., I.Z.J.), Tufts Medical Center, Boston, MA. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Proto-Oncogene Mas, Antineoplastic Agents, Cardiovascular Diseases. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: American Heart Association-American Stroke Association, NCI NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kinase inhibitors (KIs) targeting oncogenic molecular pathways have revolutionized cancer therapy. By directly targeting specific tumor-driving kinases, targeted therapies have fewer side effects compared with chemotherapy. Despite the enhanced specificity, cardiovascular side effects have emerged with many targeted cancer therapies that limit long-term outcomes in patients with cancer. Endothelial cells lining all blood vessels are critical to cardiovascular health and are also exposed to circulating levels of systemic anticancer therapies. Both on- and off-target perturbation of signaling pathways from KIs can cause endothelial dysfunction, resulting in cardiovascular toxicity. As such, the endothelium is a potential source, and also a therapeutic target for prevention, of cardiovascular toxicity. In this review, we examine the evidence for KI-induced endothelial cell dysfunction as a mechanism for the cardiovascular toxicities of vascular endothelial growth factor inhibitors, BCR-Abl (breakpoint cluster region-Abelson proto-oncogene) KIs, Bruton tyrosine inhibitors, and emerging information regarding endothelial toxicity of newer classes of KIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsProto-Oncogene MasAntineoplastic AgentsCardiovascular DiseasesHumansAnimalsSignal TransductionCardiotoxicityNeoplasmsEndothelium, VascularEndothelial CellsVascular Endothelial Growth Factor A

Stichwörter der Autor:innen

cardio-oncologycardiotoxicityendotheliumreceptors, vascular endothelial growth factortyrosine kinase inhibitors

Substanzen

Protein Kinase InhibitorsProto-Oncogene MasMAS1 protein, humanAntineoplastic AgentsVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Molecular Cardiology Research Institute (R.J.T., A.S., I.Z.J.), Tufts Medical Center, Boston, MA.
  • Division of Hematology and Oncology (R.J.T.), Tufts Medical Center, Boston, MA.

ORCID-Profile: Richard J Travers, Alec Stepanian, Iris Z Jaffe

Förderung

  • American Heart Association-American Stroke Association
  • NCI NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Travers, R. J., Stepanian, A., & Jaffe, I. Z. (2024). Endothelium as a Source of Cardiovascular Toxicity From Antitumor Kinase Inhibitors. Arteriosclerosis, Thrombosis, and Vascular Biology, 44(10), 2143-2153. https://doi.org/10.1161/atvbaha.124.319864

Vancouver

Travers RJ, Stepanian A, Jaffe IZ. Endothelium as a Source of Cardiovascular Toxicity From Antitumor Kinase Inhibitors. Arteriosclerosis, Thrombosis, and Vascular Biology. 2024;44(10):2143-2153. doi:10.1161/atvbaha.124.319864

BibTeX
@article{Travers2024,
  author = {Travers, Richard J and Stepanian, Alec and Jaffe, Iris Z},
  title = {Endothelium as a Source of Cardiovascular Toxicity From Antitumor Kinase Inhibitors},
  journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
  year = {2024},
  volume = {44},
  number = {10},
  pages = {2143--2153},
  doi = {10.1161/atvbaha.124.319864}
}
Kostenlos starten →